Pulmonary Abscess as a Complication of SARS-CoV-2 Pneumonia

Fatih Uzer¹ Sukriye Oner¹ Aykut Cilli¹

¹Department of Pulmonology, Akdeniz University Faculty of Medicine, Antalya, Turkey

Address for correspondence Fatih Uzer, MD, Department of Pulmonology, Faculty of Medicine, Akdeniz University, 07070, Antalya, Turkey (e-mail: uzerfatih@gmail.com).

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease originated in the Wuhan region of China and spread all over the world. This disease typically starts as an acute viral disease, and it is characterized by lung infiltrates and elevation of inflammatory markers. The definitive diagnosis of the disease is confirmed by polymerase chain reaction (PCR) results. Although majority of patients with positive PCR results had mild disease, 5 to 14% of them are severely affected. It has been reported in the literature that a significant proportion of adult patients develops virus-related complications. Lung abscess is one of these complications that is a suppurative infection with an air-fluid level greater than 2 cm in diameter on chest X-ray. Although there is usually a single cavity, it can also be multifocal. It was reported as a possible late-term complication of SARS-CoV-2. We are presenting two cases with lung abscess after SARS-CoV-2 treatment.

Keywords

► SARS-CoV-2
► lung abscess
► pandemic

© 2022. Libyan International Medical University Journal. All rights reserved. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; also called coronavirus disease 2019 [COVID-19]) disease was originated in the Wuhan region of China and spread all over the world. The World Health Organization declared the disease as pandemic in March 2020. This disease typically starts as an acute viral disease, and it is characterized by lung infiltrates and elevation of inflammatory markers. The definitive diagnosis of the disease is confirmed by polymerase chain reaction (PCR) results. Although majority of patients with positive PCR results had mild disease, 5 to 14% of them are severely affected.\(^1\)

It has been reported in the literature that a significant proportion of adult patients develops virus-related complications. These include thromboembolic events, arrhythmias, encephalopathy, pneumothorax, and lung abscess.\(^2\)–\(^5\) Lung abscess is a suppurative infection with an air-fluid level greater than 2 cm in diameter on chest X-ray; although there is usually a single cavity, it can also be multifocal. It was reported as a possible late-term complication of SARS-CoV-2. We are presenting two cases with lung abscess after SARS-CoV-2 treatment, followed in our clinic.

Case 1

A 70-year-old male patient presented to the emergency department with the complaint of fatigue. In physical examination, his vital signs were as follows: blood pressure—120/70 mm Hg, pulse rate—102/min, respiratory rate—24/min, temperature—36.9°C, fingertip saturation—94%. His past medical history was unremarkable. Patient had close contact with a known case of SARS-CoV-2 1 week ago. In his laboratory tests, hemoglobin was 12.7 g/dL, leukocyte count was 51,700/mm\(^3\), and C-reactive protein was 6.97 mg/dL. There was heterogeneous opacity in the left lower zone in posteroanterior (PA) chest X-ray and computed tomography (CT) showed subpleural ground-glass opacity in the bilateral lower lobes. PCR test for SARS-CoV-2 was positive. Patient was hospitalized with SARS-CoV-2 diagnosis. Hydroxychloroquine (200 mg, twice a day [BID]) and favipiravir (1,600 mg loading dose BID on day 1, followed by 600 mg BID maintenance dose for 4 days) were administered to the patient. On the third day of his hospitalization, PA chest X-ray was repeated due to worsening in shortness of breath and having a respiratory rate of 40/min. In chest X-ray, there was bilateral heterogeneous opacity. His fingertip saturation was 85%. He was intubated and transferred to intensive care unit (ICU). Piperacillin–tazobactam (4,500 mg three times daily [TID]) was added to the treatment regime. On his eighth day of ICU hospitalization, tracheostomy was performed. On his tracheal aspiration cultures taken during ICU stay, \textit{Acinetobacter baumannii}, \textit{Pseudomonas aeruginosa}, and \textit{Escherichia coli} growth was detected. According to this culture results, meropenem (1,000 mg TID) was added to the treatment regime. On the fourth day of meropenem regime, he had a high-resolution computed tomography (HRCT) of chest due to fever of 38.5°C. In HRCT, a thick-walled cavitary lesion with air-fluid leveling was seen in the upper lobe of the right lung, measuring 72 × 85 × 75 mm. Vancomycin (500 mg four times daily) and ceftazidime (2,000 mg TID) were added to the patient’s treatment with the diagnosis of lung abscess. The patient’s complaints regressed significantly, and the treatment for lung abscess was continued for 6 weeks in total. Abscess was seen to be regressed significantly in thorax CT performed 6 months after discharge (►Fig. 1).

Case 2

A 62-year-old male patient presented with complaints of cough and sputum. In his physical examination, blood pressure was 143/84 mm Hg, pulse rate was 111/min, respiratory rate was 20/min, and fever was 37.0°C. Besides having hypertension, his past medical history was unremarkable. The patient was in contact with a person diagnosed with SARS-CoV-2 3 days ago. In his laboratory tests, hemoglobin was 13.1 g/dL, leukocyte count was 10,240/mm\(^3\), and C-reactive protein was 1.71 mg/dL. There was heterogeneous opacity in the left lower zone in posteroanterior (PA) chest X-ray and computed tomography (CT) showed subpleural ground-glass opacity in the bilateral lower lobes. PCR test for SARS-CoV-2 was positive. Patient was hospitalized with SARS-CoV-2 diagnosis. Hydroxychloroquine (200 mg, twice a day [BID]) and favipiravir (1,600 mg loading dose BID on day 1, followed by 600 mg BID maintenance dose for 4 days) were administered to the patient. On the third day of his hospitalization, PA chest X-ray was repeated due to worsening in shortness of breath and having a respiratory rate of 40/min. In chest X-ray, there was bilateral heterogeneous opacity. His fingertip saturation was 85%. He was intubated and transferred to intensive care unit (ICU). Piperacillin–tazobactam (4,500 mg three times daily [TID]) was added to the treatment regime. On his eighth day of ICU hospitalization, tracheostomy was performed. On his tracheal aspiration cultures taken during ICU stay, \textit{Acinetobacter baumannii}, \textit{Pseudomonas aeruginosa}, and \textit{Escherichia coli} growth was detected. According to this culture results, meropenem (1,000 mg TID) was added to the treatment regime. On the fourth day of meropenem regime, he had a high-resolution computed tomography (HRCT) of chest due to fever of 38.5°C. In HRCT, a thick-walled cavitary lesion with air-fluid leveling was seen in the upper lobe of the right lung, measuring 72 × 85 × 75 mm. Vancomycin (500 mg four times daily) and ceftazidime (2,000 mg TID) were added to the patient’s treatment with the diagnosis of lung abscess. The patient’s complaints regressed significantly, and the treatment for lung abscess was continued for 6 weeks in total. Abscess was seen to be regressed significantly in thorax CT performed 6 months after discharge (►Fig. 1).
positive. The patient was hospitalized with the diagnosis of SARS-CoV-2. The patient was started on favipiravir with loading dose of 1,600 mg BID for the first day, followed by maintenance therapy of 600 mg BID. While his treatment was ongoing, he had a fever of 38.7°C and thorax imagings were repeated. In radiogram and thorax CT, a lung abscess was detected. Piperacillin–tazobactam (4,500 mg TID) and clarithromycin (500 mg BID) were started empirically in the patient who had no microbial growth in blood, urine, and sputum cultures. On the third day of antibiotic treatment, clinical and laboratory improvement was observed, and the treatment for abscess was continued for 6 weeks in total. The abscess was seen to be regressed in the chest X-ray taken at 6 months after discharge (Fig. 2).

Discussion

SARS-CoV-2 is an important infectious disease affecting the world, which can progress with various complications. Vigorous efforts are being made by politicians and scientists to end this pandemic. Doctors are dealing with SARS-CoV-2-related complications while trying to keep the patient from respiratory failure, which can be fatal. One of these complications is lung abscess. The cases with lung abscess in our clinic, which occurred in the early period after SARS-CoV-2, did not have any significant risk factors, except that they were male and diagnosed with SARS-CoV-2.

Lung abscess is a pulmonary infection that forms a cavity in the lung parenchyma and creates an air-fluid level in the cavity after bronchopulmonary fistula formation.6 Lung abscess can occur due to aspiration of oropharyngeal secretions, secondary to parenchymal lung diseases, bronchial obstruction, and hematogenous spread from extrapulmonary sites. Factors facilitating abscess formation in the lung could be advanced age, alcoholism, diabetes mellitus, immunosuppression, poor oral hygiene, mental retardation, and coma. One of our patients had a history of intubation due to SARS-CoV-2, and other patient did not have a risk factor other than SARS-CoV-2 that could cause an abscess.

SARS-CoV-2 pandemic is a relatively novel disease. As time passes, the early and late-term complications of the disease will be revealed in more detail. In literature, abscess after SARS-CoV-2 was defined in a few case reports. In the case reported by Renaud-Picard et al,7 a lung abscess developed after SARS-CoV-2 treatment in an obese female patient who was intubated due to SARS-CoV-2. The authors reported that intubation facilitated the development of this abscess after SARS-CoV-2 treatment. One of our cases also had a history of intubation.

The etiology of lung abscess is polybacterial in 90% of the cases.6 However, bacteria cannot always be isolated for various reasons. Muheim et al8 reported that no bacteria could be isolated in patients who developed lung abscess after SARS-CoV-2 pneumonia and the treatment was empirical. In one of our cases, bacterial growths such as “Acinetobacter baumannii, Pseudomonas aeruginosa, and Escherichia coli” were detected in the sputum culture and appropriate antibiotics were given. In our other case, no bacterial growth was detected and the treatment was empirical. Both of our cases received antibiotic regime for recommended duration and benefited from the treatment.

To conclude, SARS-CoV-2 is a disease with high mortality and morbidity, and lung imaging can be repeated in patients whose complaints do not regress despite appropriate treatment during their clinical follow-up. In patients with lung abscess, broad-spectrum antibiotic therapy can be started without hesitation.

Conflict of Interest
None declared.

References